Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

Phase 2 Completed 41 enrolled Yale University Stanley Medical Research Institute · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.

Timeline

Start: 2009-02
Primary completion: 2013-12
Completion: 2013-12

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Cannabidiol vs Placebo; p = 0.90; ANOVA NCT00588731 ↗

Publications

Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932. doi: 10.1007/s00213-018-4885-9. Epub 2018 Apr 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabidiol	Other / unclassified	600 mg	Oral